Use of a sodium-glucose cotransporter 2, or SGLT2, inhibitor combined with calorie restriction resulted in greater rates of type 2 diabetes remission compared with calorie restriction alone, according ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the company's top line.

Flagship Harbor Advisors LLC lowered its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 2.5% during the 4th ...

Investors are awaiting the company's fourth-quarter results, scheduled for February 6, for an update on the China issue.

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

Diversify Wealth Management LLC grew its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 3.6% during the ...

A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.